Up-regulation of p21 and TNF-α is mediated in lycorine-induced death of HL-60 cells

Cancer Cell International

Volumn 10, Issue , 2010, Pages

  Liu, Jing ^a   Hu, Ji liang ^a   Shi, Bi Wei ^a   He, Yan ^a   Hu, Wei Xin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; CYTOCHROME C; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYCORINE; PROTEIN BID; PROTEIN P21; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL STRAIN HL 60; CONCENTRATION RESPONSE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MITOCHONDRION; NUCLEAR IMPORT; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 77955103817     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-10-25     Document Type: Article

References (34)

1. Hu W, Kavanagh JJ. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 2003, 4:721-729. 10.1016/S1470-2045(03)01277-4, 14662428.
2. Los M, Burek CJ, Stroh C, Benedyk K, Hug H, Mackiewicz A. Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov Today 2003, 8:67-77. 10.1016/S1359-6446(02)02563-1, 12565009.
3. Reed JC. Apoptosis-based therapies. Nat Rev Drug Discov 2002, 1:111-121. 10.1038/nrd726, 12120092.
4. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995, 267:1456-1462. 10.1126/science.7878464, 7878464.
5. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002, 1:639-649.
6. Brugarolas J, Moberg K, Boyd SD, Taya Y, Jacks T, Lees JA. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma irradiation. Proc Natl Acad Sci USA 1999, 96:1002-1007. 10.1073/pnas.96.3.1002, 15340, 9927683.
7. Kondo S, Barna BP, Kondo Y, Tanaka Y, Casey G, Liu J, Morimura T, Kaakaji R, Peterson JW, Werbel B, Barnett GH. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 1996, 13:1279-1285.
8. Lincet H, Poulain L, Remy JS, Deslandes E, Duigou F, Gauduchon P, Staedel C. The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 2000, 161:17-26. 10.1016/S0304-3835(00)00586-3, 11078909.
9. Zolota V, Sirinian C, Melachrinou M, Symeonidis A, Bonikos DS. Expression of the regulatory cell cycle proteins p21, p27, p14, p16, p53, mdm2, and cyclin E in bone marrow biopsies with acute myeloid leukemia. Correlation with patients' survival. Pathol Res Pract 2007, 203:199-207. 10.1016/j.prp.2007.01.010, 17395400.
10. Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem Pharmacol 2008, 75:1262-1271. 10.1016/j.bcp.2007.10.016, 18061144.
11. Mao X, Yu CR, Li WH, Li WX. Induction of apoptosis by shikonin through a ROS/JNK-mediated process in Bcr/Abl-positive chronic myelogenous leukemia (CML) cells. Cell Res 2008, 18:879-888. 10.1038/cr.2008.86, 18663379.
12. Jin W, Di G, Li J, Chen Y, Li W, Wu J, Cheng T, Yao M, Shao Z. TIEG1 induces apoptosis through mitochondrial apoptotic pathway and promotes apoptosis induced by homoharringtonine and velcade. FEBS Lett 2007, 581:3826-3832. 10.1016/j.febslet.2007.07.008, 17659279.
13. Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S. Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 2009, 23:1446-1454. 10.1038/leu.2009.52, 2726272, 19322212.
14. Cuendet M, Christov K, Lantvit DD, Deng Y, Hedayat S, Helson L, McChesney JD, Pezzuto JM. Multiple myeloma regression mediated by bruceantin. Clin Cancer Res 2004, 10:1170-1179. 10.1158/1078-0432.CCR-0362-3, 14871997.
15. Servida F, Soligo D, Delia D, Henderson C, Brancolini C, Lombardi L, Deliliers GL. Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I. Leukemia 2005, 19:2324-2332. 10.1038/sj.leu.2403987, 16224484.
16. Chanda SK, Caldwell JS. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov Today 2003, 8:168-174. 10.1016/S1359-6446(02)02595-3, 12581711.
17. Berkov S, Codina C, Viladomat F, Bastida J. Alkaloids from Galanthus nivalis. Phytochemistry 2007, 68:1791-1798. 10.1016/j.phytochem.2007.03.025, 17475295.
18. Li SY, Chen C, Zhang HQ, Guo HY, Wang H, Wang L, Zhang X, Hua SN, Yu J, Xiao PG, Li RS, Tan X. Identification of natural compounds with antiviral activities against SARS-associated coronavirus. Antiviral Res 2005, 67:18-23. 10.1016/j.antiviral.2005.02.007, 15885816.
19. Liu J, Hu WX, He LF, Ye M, Li Y. Effects of lycorine on HL-60 cells via arresting cell cycle and inducing apoptosis. FEBS Lett 2004, 578:245-250. 10.1016/j.febslet.2004.10.095, 15589827.
20. Li Y, Liu J, Tang LJ, Shi YW, Ren W, Hu WX. Apoptosis induced by lycorine in KM3 cells is associated with the G0/G1 cell cycle arrest. Oncol Rep 2007, 17:377-384.
21. Liu XS, Jiang J, Jiao XY, Wu YE, Lin JH, Cai YM. Lycorine induces apoptosis and down-regulation of Mcl-1 in human leukemia cells. Cancer Lett 2009, 274:16-24. 10.1016/j.canlet.2008.08.029, 18829157.
22. Lamoral-Theys D, Andolfi A, Van Goietsenoven G, Cimmino A, Le Calvé B, Wauthoz N, Mégalizzi V, Gras T, Bruyère C, Dubois J, Mathieu V, Kornienko A, Kiss R, Evidente A. Lycorine, the main phenanthridine amaryllidaceae alkaloid, exhibits significant antitumour activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. J Med Chem 2009, 52:6244-6256. 10.1021/jm901031h, 19788245.
23. Liu J, Li Y, Tang LJ, Shi YW, Zhang GP, Hu WX. Treatment of lycorine on SCID mice model with human APL cells. Biomed Pharmacother 2007, 61:229-234. 10.1016/j.biopha.2007.01.003, 17336028.
24. McNulty J, Nair JJ, Bastida J, Pandey S, Griffin C. Structure-activity studies on the lycorine pharmacophore: A potent inducer of apoptosis in human leukemia cells. Phytochemistry 2009, 70:913-919. 10.1016/j.phytochem.2009.04.012, 19464034.
25. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 2008, 1:10-19.
26. Delk NA, Hunt KK, Keyomarsi K. Altered subcellular localization of tumour-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res 2009, 69:2817-2825. 10.1158/0008-5472.CAN-08-4182, 2669888, 19318554.
27. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3:421-429. 10.1016/S1535-6108(03)00110-7, 12781359.
28. Rokudai S, Aikawa Y, Tagata Y, Tsuchida N, Taya Y, Kitabayashi I. Monocytic leukemia zinc finger (MOZ) interacts with p53 to induce p21 expression and cell-cycle arrest. J Biol Chem 2009, 284:237-244. 10.1074/jbc.M805101200, 19001415.
29. Pincheira R, Castro AF, Ozes ON, Idumalla PS, Donner DB. Type 1 TNF receptor forms a complex with and uses Jak2 and c-Src to selectively engage signalling pathways that regulate transcription factor activity. J Immunol 2008, 181:1288-1298.
30. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-kappa B signalling module. Oncogene 2006, 25:6706-6716. 10.1038/sj.onc.1209933, 17072323.
31. Esposti MD. The roles of Bid. Apoptosis 2002, 7:433-440. 10.1023/A:1020035124855, 12207176.
32. Zhang L, Blackwell K, Thomas GS, Sun S, Yeh WC, Habelhah H. TRAF2 suppresses basal IKK activity in resting cells and TNF-α can activate IKK in TRAF2 and TRAF5 double knockout cells. J Mol Biol 2009, 389:495-510. 10.1016/j.jmb.2009.04.054, 2730456, 19409903.
33. Manna SK, Haridas V, Aggarwal BB. Bcl-x(L) suppresses TNF-mediated apoptosis and activation of nuclear factor-kappa B, activation protein-1, and c-Jun N-terminal kinase. J Interferon Cytokine Res 2000, 20:725-735. 10.1089/10799900050116435, 10954916.
34. Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A. The transcription factor nuclear factor-kappa B and cancer. Clin Oncol 2007, 19:154-161.